Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BNIP3P33, or BCL2 interacting protein 3 pseudogene 33, is a pseudogene related to the BNIP3 gene. A pseudogene is a genomic DNA sequence similar to a gene but generally non-functional; it usually does not encode a functional protein, and there is no evidence that BNIP3P33 itself acts as a therapeutic target, encodes an active receptor, or participates in cell signaling or disease processes. Pseudogenes may, in some cases, transcribe non-coding RNAs, which can have regulatory functions or act as competing endogenous RNAs, but there is no specific evidence for BNIP3P33's biological role. Entries describing it (such as in NCBI and Ensembl) indicate it is classified as a pseudogene with no associated protein function or drug targeting information. BNIP3P33 is not a receptor, enzyme, transporter, or therapeutic target, and there are no drugs, mechanisms of action, or disease roles attributed to it. It is best classified as a non-coding, non-target molecule. There is nothing inherently misspelled in the name, but biologically, it is "incorrect" for most drug discovery/target validation purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 33 (BNIP3P33).